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Decisions about the prescribing and reimbursement of blood glucose test strips require consideration of information about the costs and clinical benefits. 9, 10 As part of a larger initiative to determine the optimal use of this technology, we sought to determine the cost-effectiveness of self-monitoring of blood glucose for patients with type 2 diabetes who do not use insulin, based on data from our systematic review 11 of the available clinical evidence.
Results: Based on a clinically modest reduction in hemoglobin A 1C of 0.25% (95% confidence interval 0.15-0.36) estimated from the systematic review, the UKPDS model predicted that self-monitoring performed 7 or more times per week reduced the lifetime incidence of diabetes-related complications compared with no self-monitoring, albeit at a higher cost (incremental cost per quality-adjusted life year $113 643). The results were largely unchanged in the sensitivity analysis, although the incremental cost per qualityadjusted life year fell within widely cited cost-effectiveness thresholds when testing frequency or the price per test strip was substantially reduced from the current levels.
Interpretation: For most patients with type 2 diabetes not using insulin, use of blood glucose test strips for frequent self-monitoring (≥ 7 times per week) is unlikely to represent efficient use of finite health care resources, although periodic testing (e.g., 1 or 2 times per week) may be costeffective. Reduced test strip price would likely also improve cost-effectiveness.
) The model estimates the risks of 7 diabetes-related complications based on data obtained from 3642 patients with type 2 diabetes who were enrolled in UKPDS. Projections from this model have been validated using published clinical and epidemiological studies. 13 Relevant clinical outcomes associated with selfmonitoring of blood glucose in adults with type 2 diabetes not using insulin were derived from our systematic review 11 of randomized controlled trials and observational studies comparing self-monitoring with no self-monitoring. We assessed a number of outcomes, including hemoglobin A 1C (HbA 1C ) , hypoglycemia, quality of life, long-term complications of diabetes and mortality. The methodology and results of the review have been reported in full. 11 The UKPDS model simulates the occurrence of clinical events over the expected remaining lifetime of a patient with type 2 diabetes (maximum 40 years). Simulated patients were characteristic of those enrolled in randomized controlled trials included in the systematic review. 11 The ages and baseline risk factors for diabetes-related complications of the simulated patients (e.g., baseline HbA 1C level, systolic blood pressure, cholesterol level) have been reported.
14 Data on the history of 7 major diabetes-related complications captured in the UKPDS Outcomes Model (Appendix 1) were not reported in the randomized controlled trials included in the systematic review. Therefore, we assumed that patients in the hypothetical cohort in the base-case analysis did not have a history of these complications. We made this assumption because most randomized controlled trials excluded patients with impending diabetes-related complications or a history of serious disease, and because less than 1% of patients in Canada with type 2 diabetes aged 45-65 years have a history of stroke, blindness, amputation or renal disease. [14] [15] [16] We performed this analysis from the perspective of a Canadian ministry of health. 17 We obtained the unit costs for blood glucose test strips ($0.73/strip) and dispensing fees ($7.00 per 100 strips) from the Ontario Public Drug Program. 18, 19 We did not incorporate the costs for glucometers and lancets, because they are often made available to patients at no charge by manufacturers 20 and they are usually not covered by public drug plans. We assumed an average daily consumption of 1.29 blood glucose test strips per patient on the basis of the weighted average of actual (where reported) or perprotocol testing frequencies across randomized controlled trials included in the systematic review. This estimate closely coincided with the results of a recent utilization study of Ontario Public Drug Program beneficiaries. 3 Resource utilization and costs (Table 1 ) associated with managing diabetes-related complications were obtained from the Ontario Ministry of Health and Long-term Care. 23 Inpatient, outpatient and emergency department visits, prescription drug claims, long-term care and home care costs for managing diabetes-related complications were included in the model. 23 The costs were inflated to 2008 Canadian dollars using the Health Component of the Canadian Consumer Price Index.
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Both costs and quality-adjusted life-years were discounted at a rate of 5%, as recommended by the guidelines of the Canadian Agency for Drugs and Technologies in Health.
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Outcomes
The primary outcome measure in the current analysis was quality-adjusted life-years, which capture both quantity and quality of life. We obtained quality weights for included health states from a US catalogue of EuroQol 5-dimension (EQ-5D) scores. 21, 22 Patients with noninsulin-treated type 2 diabetes without a history of diabetes-related complications were assumed to have an EQ-5D score of 0.753. 21, 22 Disutilities associated with diabetes-related complications are reported in Table 1 .
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Statistical analysis
We performed 1-, 2-and multi-way sensitivity analyses to examine the robustness of the results to changes in the parameters and model assumptions. A number of randomized controlled trials included in the systematic review included patients who were taking either oral antidiabetes agents or made lifestyle interventions. We therefore assessed the effect of HbA 1C inputs derived from pooling across the subset of randomized controlled trials in which all 21 while those who self-monitored had an annual cost of $1507 20 plus the cost of the blood glucose test strips. †Inflated to 2008 Canadian dollars using the health component of the Consumer Price Index. ‡A utility is a quantitative expression of an individual's preference for a health state; 1 represents a state of perfect health and 0 represents a state equivalent to death. 25 §Management costs for a fatal myocardial infarction are $9039; management costs for a fatal stroke are $8505. 21 **Utility decrements were not available from the US catalogue;
22,23 therefore, they were obtained from another source that utilized the EQ-5D instrument. 19 patients received oral antidiabetic agents or those in which all patients received nonpharmacological interventions. We tested the effect of varying the cost of the test strips, testing frequency, baseline HbA 1C levels and patient characteristics. We also tested including a utility decrement for symptomatic hypoglycemia. The detailed results from additional sensitivity analyses are reported elsewhere. 27 We generated costeffectiveness acceptability curves for the reference case, as well as for alternative testing frequencies and test strip prices, to illustrate the probability that the self-monitoring of blood glucose is cost-effective across a range of decision-makers' willingness-to-pay thresholds.
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Results
Our systematic review 11 identified 7 randomized controlled trials, [29] [30] [31] [32] [33] [34] [35] enrolling a total of 2270 patients with type 2 diabetes managed with oral antidiabetes agents or lifestyle measures alone. These trials compared self-monitoring of blood glucose with no self-monitoring. The pooled difference in HbA 1C was statistically significant in favour of selfmonitoring (weighted mean difference -0.25%, 95% confidence intervals [CI] -0.36% to -0.15%). The results were similar in a number of subgroup analyses, including the intensity of education about the interpretation and application of the test results, testing frequency, diabetes duration and baseline HbA 1C level. Based on limited evidence, selfmonitoring has failed to show consistent benefits in terms of quality of life, patient satisfaction, hypoglycemia, long-term complications of diabetes and mortality. These outcomes were therefore not included in the cost-effectiveness analysis of the reference case.
The HbA 1C benefit of self-monitoring from the systematic review, 11 when analyzed using the UKPDS Outcomes Model, translated into small differences (ranging from 0.08% to 0.40%, depending on the outcome) in cumulative incidence rates of diabetes-related complications ( Table 2 ). The numbers of patients who would need to perform selfmonitoring to avert 1 diabetes-related complication over a 40-year period ranged from 228 to 1299 (Table 2 ). Selfmonitoring of blood glucose was associated with an additional 0.024 qualityadjusted life-years and increased lifetime costs of $2711, resulting in an incremental cost-utility ratio of $113 643 per quality-adjusted life-year gained (Table  3) . Cost-effectiveness acceptability curves ( Figure 1 and Figure 2 ) revealed a probability of less than 10% that self-monitoring would be cost-effective at a willingness-to-pay threshold of $50 000 per quality-adjusted life-year, and a 40% probability of costeffectiveness at a threshold of $100 000 per quality-adjusted life-year. 10 The reduction in HbA 1C associated with self-monitoring in the only randomized trial that reported results for patients not using pharmacotherapy for diabetes 30 was smaller than in the overall analysis (weighted mean difference -0.05%, 95% CI -0.23 to 0.33), resulting in a cost per quality-adjusted lifeyear gained of $292 144. The cost per quality-adjusted lifeyear based on the pooled HbA 1C difference in the subset of randomized controlled trials 30, 31, 35 in which all patients used oral antidiabetes agents was $91 724 per quality-adjusted life-year gained. The results were highly sensitive to the price of the test strips and, to a lesser extent, testing frequency (Table 4 ; Figure 1 and Figure 2) , 1, 2, 7, [14] [15] [16] 23, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] but the results were largely unchanged if we varied most other parameters and assumptions. 
Interpretation
Our cost-effectiveness analysis was based on a systematic review of the available clinical evidence, 11 which showed a clinically modest 43 benefit in HbA 1C levels among patients with type 2 diabetes who self-monitored their blood glucose levels. This result translated into a small reduction in diabetes-related complications in the economic model. We found that selfmonitoring at a frequency of about 9 tests per week was associated with an incremental cost of $113 643 per qualityadjusted life-year gained, relative to no self-monitoring. Thus, the clinical benefits of self-monitoring and the associated costsavings do not offset the cost of the blood glucose test strips.
In our sensitivity analyses, we explored conditions under which cost-effectiveness estimates may vary. The results did not change substantially with changes in the assumed HbA 1C benefit CMAJ 4 Figure 1 : Cost-effectiveness acceptability curves for different prices per blood glucose test strip. These curves show the probability that performing self-monitoring of blood glucose (SMBG) is cost-effective relative to not performing self-monitoring in patients with type 2 diabetes who are not using insulin, across a range of decision-makers' willingness to pay-thresholds.
of self-monitoring, higher baseline HbA 1C levels, or when the cohort was modified to reflect patient characteristics (e.g., diabetes-related complications, duration of diabetes) observed in the Canadian setting (Table 4) . Cost-effectiveness estimates, however, were highly sensitive to changes in the price per test strip and testing frequency. Cost-effectiveness acceptability Note: CI = confidence interval, DICE = Diabetes in Canada Evaluation, HbA 1c = hemoglobin A1c, ΔHbA 1c = changes in HbA 1c levels, ICUR = incremental cost-utility ratio, OAD = oral antidiabetes drug, OALY = quality-adjusted life-year, RCT = randomized controlled trial, WMD = weighted mean difference. *Instruction in self-interpretation and application. †One-way sensitivity analysis in which the HbA 1c estimate of effect was held constant at -0.25% (95% CI -0.36% to -0.15%) favouring self-monitoring and testing frequency is varied.
‡Proportion of patients with a history of complications reflective of patients in the Diabetes in Canada Evaluation and Ontario and Alberta Diabetes Atlases (i.e., 1% of patients were assumed to have history of blindness, [13] [14] [15] end-stage renal disease, 13-15 amputation; 13-15,32 4% 36,37 and 2% 32 of patients had history of atrial fibrillation and peripheral vascular disease on diagnosis of diabetes; 2% have history of stroke; 9% have history of myocardial infarction; [13] [14] [15] 4% have congestive heart failure; [13] [14] [15] and 10% had a history of ischemic heart disease [13] [14] [15] ; average time since event was based on data from the Ontario Diabetes Economic Model 16 ). §Baseline HbA 1c = 8.3%; WMD in HbA 1c %: -0.24 (-0.36,-0.11); mean age = 61 yr; mean duration of diabetes = 4.9 yr; frequency = 1.08 test strips/day; cost of test strip = Can$0.73/strip; time horizon = 40 yr; discount rate = 5%; we assumed no history of diabetes-related complications, because these data were not reported in 3 RCTs. 1, 2, 6 **Based on data from Barnett and colleagues, 26,27,31 we assumed that 7% of patients would experience a symptomatic hypogylcemic episode with an excess of 2.38 episodes per year in the no self-monitoring arm. For each episode, we assumed that patients move to a health state characterized by moderate anxiety, with or without depression and have some problems with performing usual activities. 38 Consequently, a disutility of 0.167 38 was used for 15 min for each episode; baseline HbA 1c = 8.3%; WMD in HbA 1c %: -0.24 (-0.36, -0.11); mean age = 61 yr; mean duration of diabetes = 4.9 yr; frequency = 1.08 test strips/day; cost of test strip = Can$0.73/strip; time horizon = 40 yr; discount rate = 5%; we assumed no history of diabetes-related complications, because these data were not reported in 3 RCTs in which patients used oral antidiabetes drugs.
26,27,31 † †Baseline HbA 1c = 7.5%; WMD in HbA 1c %: -0.05 (-0.33, 0.23); mean age = 66 yr; mean duration of diabetes = 3 yr; frequency = 0.71 test strips/day; cost of test strip = Can$0.73/strip; time horizon = 40 yr; discount rate = 5%; we assumed no history of diabetes-related complications, because these data were not reported in 3 RCTs. 1, 2, 6 curves showed that a greater than 50% reduction in the price per test strip would result in a substantial increase in the probability that self-testing is cost-effective. Results from 1-and 2-way sensitivity analyses also suggested that lower testing frequencies (e.g., 1-2 tests per week) would be the most likely to yield favourable cost-effectiveness estimates. This is not surprising because the incremental HbA 1C benefit of each subsequent test per day is likely to be progressively smaller, while the cost of test strips increases linearly with the number used. Further welldesigned randomized controlled trials are needed to assess the role of self-monitoring at lower testing frequencies in patients with type 2 diabetes who are not using insulin.
Our results differ from those reported in earlier incremental cost-utility analyses. 36, 44, 45 Two of the previous studies 36, 44 found more favourable cost-effectiveness estimates, likely because of the use of data from an observational study, 37 which found larger HbA 1C differences in favour of self-monitoring than our systematic review. Conversely, the other economic study 45 reported results less favourable to self-monitoring primarily because the HbA 1C results were from a single clinical trial. Differences in utility decrements may also explain some of the differences in the results between these studies. Health-related quality-of-life scores in 2 earlier analyses 36, 44 were based on data from patients with type 2 diabetes 24 and the authors did not control for nondiabetes-related complications and other confounding variables such as income, education, ethnicity and number of comorbidities, all of which affect health-related quality of life. In contrast, we obtained utility decrements from a community-based EQ-5D catalogue in the United States, 21, 22 which was adjusted for determinants of health (e.g., age, sex, income, education) and chronic conditions other than diabetes.
The choice of economic model may also contribute to differences between our analysis and previous studies. We used the UKPDS Outcomes Model, 12 while 2 previous studies 36, 44 used the Center for Outcomes Research (CORE) Diabetes Model. 46 The UKPDS Outcomes Model uses updated regression equations derived from UKPDS68, 12 while the CORE Diabetes Model 46 uses regression equations derived from the older UKPDS56 Risk Engine. 47 Thus, the UKPDS Outcomes Model 12 provides a more accurate estimate of events examined in UKPDS because it uses a wider variety of inputs, including knowledge of previous events, and incorporates updated risk factor data over time.
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Limitations
Our study had several limitations. First, cost-effectiveness results are limited by available clinical evidence.
11 Second, the model used HbA 1C , a surrogate outcome, to project the occurrence of long-term consequences related to diabetes. The validity of this outcome continues to be debated in the literature, particularly for cardiovascular outcomes in patients with type 2 diabetes. 48, 49 Thus, the benefits of self-monitoring blood glucose in terms of reduced rates of complications may be overstated. Third, the UKPDS model 36 does not explicitly incorporate a number of morbidities (e.g., peripheral neuropathy, ulceration) related to diabetes. As well, some complications are represented as a single outcome (e.g., blindness, endstage renal disease) in the model rather than intermediate states such as (e.g., retinopathy, nephropathy) that may themselves be associated with reduced health-related quality of life. Since a reduced incidence of these outcomes because of selfmonitoring and the resulting benefits in terms of health-related quality of life and reduced treatment costs may not be captured, the use of the UKPDS model may result in a slight overestimation of the incremental cost-effectiveness ratios. 12 Longterm follow-up data from UKPDS may provide additional data for these states, at which time a reassessment of the costeffectiveness of self-monitoring in patients with type 2 diabetes may be warranted.
Finally, the analysis of the reference case did not incorporate hypoglycemic episodes, including severe hypoglycemia. Episodes of hypoglycemia, however, are infrequent 2 in patients with type 2 diabetes not using insulin, with the exception of those using insulin secretagogues (i.e., sulfonyureas, meglinatides). Additionally, there is little evidence that use of self-monitoring alters the risk of hypoglycemia, even in patients using sulfonylureas. 35 If future studies reveal that selfmonitoring of blood glucose is associated with a reduced risk of hypoglycemia, especially severe hypoglycemia, this analysis should be revisited given the potential impact of this complication on clinical outcomes and resource utilization.
Conclusion
We found that self-monitoring of blood glucose was associated with a modest reduction in HbA 1C in patients with type 2 diabetes not treated with insulin. Within the limitations of modelling and the available clinical data, frequent use of selfmonitoring in this population is associated with unfavourable cost-effectiveness estimates and is unlikely to represent an efficient use of finite health care resources. This result did not change substantially with changes to a number of inputs, including the type of antidiabetes therapy, degree of glycemic control at baseline and history of diabetes-related complications. However, reduced frequency (e.g., 1 or 2 times per week) or a reduction in the price of test strips would likely improve the cost-effectiveness of routine self-monitoring in this population.
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